

Probiomics Limited ABN 97 084 464 193

Suite G09, 1 Central Avenue Australian Technology Park Eveleigh NSW 1430

P: +61 2 9209 4268 F: +61 2 9209 4256 W: www.probiomics.com.au

The Australian Stock Exchange Limited Companies Announcements Office SYDNEY

24 April 2008

Extension of Share Purchase Plan.

Further to the company's ASX release of the 18th April 2008, the directors of Probiomics Limited have decided to extend the current Share Purchase Plan by three weeks, rather than two weeks as previously advised. The revised closing date of the offer is the 9th May 2008. The offer has been extended to allow shareholders to make an informed decision about investing in the SPP, in light of the market update with respect to the proposed acquisition of Minomic International Limited released to the market on the 16th April 2008.

Ashok Jairath Company Secretary

About Probiomics Limited

Probiomics has proprietary ownership of a unique probiotic strain – PCC®

PCC® has been clinically proved to have superior qualities to other probiotic strains – particularly in promoting systemic immune response.

Probiomics' commercial objective is to earn royalties from licensing PCC® to distribution companies selling products in global markets.